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Abstract
Cervical cancer is one of the most common cancers in women worldwide, being high-risk group the HPV infected, the
leading etiological factor. The raf kinase inhibitory protein (RKIP) has been associated with tumor progression and
metastasis in several human neoplasms, however its role on cervical cancer is unclear. In the present study, 259 uterine
cervix tissues, including cervicitis, cervical intraepithelial lesions and carcinomas, were analyzed for RKIP expression by
immunohistochemistry. We found that RKIP expression was significantly decreased during malignant progression, being
highly expressed in non-neoplastic tissues (54% of the samples; 73/135), and expressed at low levels in the cervix invasive
carcinomas (,15% (19/124). Following in vitro downregulation of RKIP, we observed a viability and proliferative advantage
of RKIP-inhibited cells over time, which was associated with an altered cell cycle distribution and higher colony number in a
colony formation assay. An in vitro wound healing assay showed that RKIP abrogation is associated with increased
migratory capability. RKIP downregulation was also associated with an increased vascularization of the tumors in vivo using
a CAM assay. Furthermore, RKIP inhibition induced cervical cancer cells apoptotic resistance to cisplatin treatment. In
conclusion, we described that RKIP protein is significantly depleted during the malignant progression of cervical tumors.
Despite the lack of association with patient clinical outcome, we demonstrate, in vitro and in vivo, that loss of RKIP
expression can be one of the factors that are behind the aggressiveness, malignant progression and chemotherapy
resistance of cervical cancer.
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Introduction
Cervical cancer is the third most commonly diagnosed cancer
and the fourth leading cause of cancer death in females worldwide,
accounting for 9% (529.800) of the total new cancer cases and 8%
(275.100) of the total cancer deaths among females in 2008 [1].
Persistent infection with high-risk types of human papillomavirus
(HPV) is a sine-qua-non condition for cervical cancer development.
HPVs infect epithelial cells and cause a variety of lesions ranging
from common warts to cervical neoplasia and cancer [2–4].
Tumors of the cervix are divided into three different histological
subtypes: Uterine squamous cell carcinomas (SCC) is the most
frequent, followed by adenocarcinoma (AC) and adenosquamous
carcinoma (ASC), which is an uncommon subtype [5]. HPV
infection alone is not enough for triggering cervical cancer and
HPV-mediated oncogenesis also requires the accumulation of
additional genetic changes that occur over time following initial
infection [6]. It may take several years for an in situ neoplasm to
progress to an invasive carcinoma. The mechanism of clonal
evolution, which involves the selection of cells with invasive or
metastatic potential, also remains unsolved.
Raf kinase inhibitory protein (RKIP; also known as PEBP1, for
phosphatidylethanolamine-binding protein1), as indicated by the
name, was first identified as the endogenous inhibitor of the RAF/
MEK/ERK pathway, inhibiting Raf-1 activation [7–9]. Actually,
RKIP has been implicated in various intracellular signaling
pathways that control cell growth [10,11], motility [12,13],
epithelial to mesenchymal transition (EMT) [14] and differentia-
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tion [15]. RKIP is widely expressed in normal human tissues,
highlighting its role in various physiologic processes [16], but is
considered to be a metastasis suppressor in cancer [17], being its
loss or reduced expression associated with malignancy and
prognosis in many types of metastatic and aggressive cancers
[10,11,18–34].
A previous study, done in a small fraction of patients, found by
expression microarray analysis that RKIP is one of the genes that
is differentially expressed between tumor samples from cervical
cancer patients with or without lymph node metastasis [35]. More
recently, it was found in a large series of patients that RKIP
protein is significantly downregulated in cervical cancer and
lymph node metastasis [36]. Additionally, another study with
HeLa cervical cancer cells showed that RKIP, through regulation
of the ERK pathway, has an important role in mitotic checkpoint
regulation [37]. Hence, the previous findings, prompted us to
elucidate the biological role of RKIP in cervical cancer malignant
progression and chemotherapy response. Therefore, we first
assessed the expression levels of RKIP protein in both non-
malignant and tumoral cervical samples, and assessed its role in
the clinical outcome of cervical cancer patients. Secondly, we
assessed in vitro and in vivo the biological function of RKIP
downregulation in cervical cancer malignancy and chemotherapy
response.
Materials and Methods
Tissue Samples
For the present work, 259 cervical tissues were analyzed, which
included 45 cervicitis, 47 low-grade squamous intraepithelial
lesions (LSIL), 43 high-grade squamous intraepithelial lesions
(HSIL), 70 squamous cell carcinomas (SCC), 41 adenocarcinomas
(AC) and 13 adenosquamous carcinomas (ASC) (Table 1). The
paraffin samples containing the cervical non-malignant lesions
were retrieved from the files of the Pathology division of Adolfo
Lutz Institute Sa˜o Paulo, Brazil, and the invasive cervical tumor
samples were retrieved from Arau´jo Jorge Hospital and School of
Medicine of the Federal University of Goia´s (Goiaˆnia, Goias State,
Brazil). All histopathological diagnoses were reviewed by the
authors and categorized according to the WHO classification. All
patients with cervical cancer were females of Brazilian origin, with
a mean age of 49 years (range 23–74 years). Follow-up data was
available for 72 patients, and collected through direct interview
with patients or their relatives, and by review of in-hospital patient
files. The median follow-up time (overall survival) was 35.5642.0
months (range, 2–144 months).
All the samples enrolled in the present study were unlinked and
unidentified from their donors. Due the retrospective nature of the
study, no written informed consent from patients was obtained.
The Local Ethical Review Committees of the involved institutions
(Ethics committee in Human Research of Adolfo Lutz Institute
Sa˜o Paulo and of Arau´jo Jorge Hospital from School of Medicine
of the Federal University of Goia´s, Brazil) approved the work and
waived the need for written informed consent.
Cell Lines
For the present study it were used three cervical carcinoma cell
lines: HeLa cell line, kindly provided by Dra Elsa Logarinho
(IBMC, Portugal) [38], SiHa and C-33A cell lines that were kindly
provided by Dra Luisa Villa (INCT-HPV, Brazil) [39]. All the cell
lines were grown and maintained at 37uC and 5% CO2 in
Dulbecco’s Modified Eagle’s Medium (DMEM 16, High Glucose;
Gibco, Invitrogen) supplemented with 10% Fetal Bovine Serum
(FBS; Gibco, Invitrogen) and 1% penicillin/streptomycin solution
(Gibco, Invitrogen) (DMEM-10).
Drugs
Cisplatin (cis-Diammineplatinum(II) dichloride) was obtained
from Sigma-Aldrich and diluted in 0.9% NaCl for a stock solution
of 10 mM. The drug was subsequently prepared as intermediated
dilutions to obtain an equal quantity of drug vehicle (1% final
concentration) in each of the conditions studied. In all experi-
mental conditions the drugs were diluted in 0.5% FBS culture
medium (DMEM-0.5).
Immunohistochemistry and Immunocytochemistry
Analysis of RKIP
Histological slides with 4 mm-thick tissue sections were subjected
to immunohistochemical analysis according to the streptavidin-
biotin peroxidase complex system (UltraVision Large Volume
Detection System Anti-Polyvalent, HRP; LabVision Corporation),
using the primary antibody raised against RKIP (Millipore,
reference 07–137) diluted 1:600, incubation 1H at RT, as
previously described [18,25,40,41].
Sections were scored double-blind for cytoplasmatic expression
following a semi-quantitative criterion: (2), 0% of immunoreactive
cells; (+), ,5% of immunoreactive cells; (++), 5–50% of
immunoreactive cells; and (+++), .50% of immunoreactive cells.
Samples with scores (2) and (+) were considered negative, and
those with scores (++) and (+++) were considered positive.
For RKIP immunocytochemical analysis of cervical carcino-
ma cell lines, the cells were plated on glass coverslips placed
into 12-well plates, and allowed to adhere overnight. The
immunocytochemistry procedure was performed as previously
described [41].
Table 1. RKIP expression in cervical lesions.
RKIP Expression
Type of Lesion N Negative (%) Positive (%) p
Cervicitis 45 16 (35.6) 29 (64.5)
LSIL
CIN1 47 26 (55.3) 21 (44.7)
HSIL
CIN2 16 6 (37.5) 10 (62.5)
CIN3 27 14 (51.9) 13 (48.1)
LSIL 47 26 (55.3) 21 (44.7) 0.404
HSIL 43 20 (46.5) 23 (53.5)
Invasive Carcinoma
AC 40 33 (80.5) 8 (19.5) 0.643
SCC 70 61 (87.1) 9 (12.9)
ASC 13 11 (84.6) 2 (15.4)
Cervicitis 45 16 (35.6) 29 (64.5) 0.087
SIL 90 46 (51.1) 44 (48.9)
Benign Lesions 135 62 (46.0) 73 (54.0) ,0.001
Cervical Cancer 124 105 (84.7) 19 (15.3)
Cervical intraepithelial neoplasia (CIN); Low-grade squamous intraepithelial
lesions (LSIL); high-grade squamous intraepithelial lesions (HSIL); squamous cell
carcinomas (SCC); adenocarcinomas (AC); adenosquamous carcinomas (ASC).
doi:10.1371/journal.pone.0059104.t001
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Generation of shRKIP Stably Expressing Cell Lines
For generation of cell lines stably expressing shRKIP, we used
the PQY15 vector, containing a 19 bp shRNA for RKIP, as
previously described [37,41,42]. The transfection was done by
using the FUGENE HD reagent (Roche) as recommended by the
manufacturer, with 2 mg of plasmid at a ratio of 6:2 (Reagent:-
Plasmid). The cells (26105) were plated onto a 12-well plate until
80% of confluence and transfected in DMEM medium, without
FBS or antibiotics addition, during 24 hours [41]. After that, stable
transfectants were selected with 0.5 mg/ml (HeLa) or 2 mg/ml (C-
33A and SiHa) of puromycin in DMEM-10. The empty vector
was also transfected as a control.
Western Blot Analysis
The cells were plate in a 6 well plate at a density of 86105 cells
per well and allowed to adhere at least 24 hours. The cells were
serum starved for 6 hours before protein isolation. When
necessary, the cells were also stimulated with 10 ng/ml of EGF
by 10 minutes before the end of the 6 hours of starvation. Also, for
cisplatin experiments the cells were exposed to various concen-
trations of cisplatin for an additional period of 24 hours in
DMEM-0.5. The cells were scraped in cold PBS and lysed in
buffer containing 50 mM Tris pH 7.6–8, 150 mM NaCl, 5 mM
EDTA, 1 mM Na3VO4, 10 mM NaF, 10 mM NaPyrophosphate,
1% NP-40 and 1/7 of Protease cocktail inhibitors (Roche).
Western blotting was done using standard 12% SDS-PAGE gel,
loading 20 mg of protein per lane, with detection by enhanced
chemiluminescence (SuperSignal West Femto Maximum Sensitiv-
ity Substrate, Pierce). RKIP expression was measured using a
specific antibody against RKIP (dilution 1:2000, Upstate Biotech-
nology). Activated ERK and EGFR were assessed using the
antibody phospho-p44/42 MAPK (Thr202/Tyr204) and phos-
pho-EGFR (Y1068) (dilution 1:1000, Cell Signaling Technology).
The total form of ERK and EGFR were also assessed with the
antibodies p44/42 MAPK (Erk1/2) (clone 137F5, dilution 1:1000,
Cell Signaling Technology) and EGFR (dilution 1:500, clone
31G7, ZYMED Laboratories). For apoptosis assessment it were
used antibodies against cleaved PARP (clone Asp214, dilution
1:1000, Cell Signaling Technology), cleaved caspase-9 (clone
Asp330, dilution 1:1000, Cell Signaling Technology) and PARP
(dilution 1:1000, Cell Signaling Technology). For loading control
we used b-Tubulin (clone AA2, dilution 1:5000, Upstate
Millipore). All the primary antibodies were incubated for one
hour at RT.
Blots detection was done by chemiluminescence (ECL Western
Blotting Detection Reagents, RPN2109, GE Healthcare) in
ImageQuantTM LAS 4000 mini (GE Healthcare) or using X100
Hyperfilm ECL (Amersham, GE Healthcare).
Cell Viability and Proliferation Assays
The cells were plated into 96-well plates in triplicate at a density
of 36103 cells per well and allowed to adhere overnight in
DMEM-10. After 6 hours of serum starvation the viable or
proliferative cells were quantified using the Cell Titer96 Aqueous
cell proliferation assay (Promega) or with Cell Proliferation
ELISA, BrdU (colorimetric, Roche Applied Science) and used
for the time 0 value. Then, cells were incubated in DMEM
medium without serum during 24, 48 and 72 hours and cell
viability and proliferation was again assessed by Cell Titer96
Aqueous cell proliferation assay and Cell Proliferation ELISA,
BrdU (colorimetric), respectively. The results were calibrated to
the starting value (time 0 h, considered as 100% of viability/
proliferation) and expressed as the mean 6 SD. The assay was
done in triplicate at least three times.
To determine the concentration at which 50% of the cell
growth is inhibited by cisplatin treatment (IC50 concentration), the
cells were plated into 96-well plates at a density of 36103–56103
cells per well and allowed to adhere overnight in DMEM-10.
Subsequently, the cells were treated with increasing concentrations
of the drug diluted in DMEM-0.5. After 48 hours, cell viability was
quantified using Cell Titer96 Aqueous cell proliferation assay
(MTS) (Promega). The results were expressed as mean 6 SD
viable cells relatively to drug vehicle alone (considered as 100%
viability). The IC50 concentration was calculated by nonlinear
regression analysis using GraphPad Prism software.
Wound Healing Migration Assay
The cells were seeded in 6-well plates and cultured to at least
95% of confluence. Monolayer cells were washed with PBS and
scraped with a plastic 200 mL pipette tip and then incubated with
fresh DMEM medium without serum. The ‘‘wounded’’ areas were
photographed by phase contrast microscopy at 12, 24 or 48 hours’
time points. The relative migration distance was calculated by the
following formula: percentage of wound closure (%) = 100 (A–B)/
A, where A is the width of cell wounds before incubation, and B is
the width of cell wounds after incubation [41]. Results are
expressed as the mean 6 SD. The assay was done in triplicate at
least three times.
Cell Cycle Analysis
The cells were plated in a 6-well plate at a density of 26105 cells
per well and allowed to adhere overnight. After 6 hours of serum
starvation the cells were incubated with fresh DMEM medium
without serum during 24 hours. Cells were tripsinized and fixed in
70% ethanol at least 30 minutes and then stained during 1 hour at
50uC with a propidium iodide (PI) solution (20 mg/mL of PI and
250 mg/mL of RNAse in a solution of 0.1% Triton X-100 in PBS).
Cell cycle analysis of the PI stained cells was performed by flow
cytometry (LSRII, BD Biosciences). The percentage of cells in
each phase of the cell cycle was determined with the software
FlowJo version 7.6.3. The results were expressed as the mean 6
SD of the percentage of cells in G1 phase or G2/M plus S phase
[41]. The assay was done in triplicate at least three times.
Soft Agar Colony Formation Assay
The soft-agar colony formation assay was done using standard
methods, as previously described by us [43]. Briefly, 1 mL
underlayers (base agar layers) consisting of 0.6% agar medium
were prepared in 6-well plates by combining equal volumes of
1.2% Noble agar with either 26DMEM medium with 20% FBS.
The cells were trypsinized, centrifuged, and ressuspended in
0.35% agar medium (top agar layer; equal volumes of 0.7% Noble
agar and 26DMEM with 20% FBS); 26103 cells were then plated
onto the previously prepared base agar layers. The cells were
incubated at 37uC in a humidified 5% CO2 atmosphere for 15
days and the colonies formed stained with 0.05% violet crystal for
15 minutes. Stained colonies were photographed using a
stereomicroscope (Olympus S2616) and a digital camera (Olym-
pus DP71) and counted with Image J Software. Only colonies with
a size greater than 775 mm2 (approximately 31.4 mm of diameter)
were counted [43]. Results are expressed as the mean 6 SD. The
assay was done in triplicate at least three times.
Chick Chorioallantoic Membrane (CAM) Assay
To assess in vivo tumor proliferation and angiogenesis we used
the CAM assay as previously described [41,43]. Fertilized chicken
eggs were incubated at 37uC and 70% humidity, and on day 3 of
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development, a window was made into the shell, which was sealed
with tape, and the eggs were returned to the incubator. On day 9
of development, small plastic rings were placed on the CAM and
on day 10 of development 36106 cells, resuspended in 20 ml of
DMEM medium, were injected in the rings over the CAM. On
day 17 of development, the tumor formed was photographed in ovo
using a stereomicroscope (Olympus S2616), and the perimeter of
the tumor was measured using Cell B software (Olympus). Results
are expressed as the mean 6 SD.
Finally, the chicken eggs were sacrificed at 280uC for 10
minutes, and CAM and tumors were fixed with paraformaldehyde
at 4% and photographed ex ovo for blood vessels counting. The
tumors were embedded in paraffin and processed for histological
analysis.
Statistical Analysis
Correlations between RKIP expression and clinical data from
patients were performed using the chi-square test (x2-test).
Cumulative survival probabilities were calculated using the
Kaplan-Meier method. Differences between survival rates were
tested with the log-rank test. The statistical analysis was performed
using SPSS software for Windows, version 17.0. For in vitro and
in vivo assays, single comparisons between the different conditions
studied were done using Student’s t test, and differences between
groups were tested using two-way analysis of variance (ANOVA).
Statistical analysis was done using Graph Pad Prism version 5. The
level of significance in all the statistical analysis was set at p,0.05.
Results
RKIP Expression in Cervical Tissues
An immunohistochemistry approach was done to detect RKIP
protein expression and distribution in cervical lesions (Fig. 1).
Cytoplasmatic positive expression of RKIP was observed in
64.5% (29/45) of the cervicitis samples, in 44.7% (21/47) of LSIL
and 53.5% (23/43) of HSIL (Table 1) (Fig. 1A and B). No
significant differences were observed in the expression levels of
RKIP between LSIL and HSIL (p=0.404), and also between
cervicitis and squamous intraepithelial lesions (SIL) in general
(p=0.087), Table 1). Concerning malignant lesions, RKIP was
present at low levels, with only 19.5% (8/41) of AC, 12.9% (9/70)
of SCC and 15.4% (2/13) of ASC depicting positive staining
(Table 1) (Fig. 1C and D). No significant differences were observed
between RKIP expression in the different malignant lesions
studied (p=0.643, Table 1). However, when grouping the benign
lesions (cervicitis and SIL) and the malignant lesions (AC, SCC
and ASC), a statistical significant decrease of RKIP expression was
observed in cervical cancer samples (p,0.001) when compared
with the benign lesions (Table 1).
No correlations were found between RKIP expression and
clinical features of patients, such as age, presence of metastasis and
follow-up data, independently of the histological type (p.0.05,
Table 2).
RKIP Expression and Modulation of ERK Pathway in
Cervical Cancer Cell Lines
To study the role of RKIP in cervical cancer, we first screened
for RKIP expression in human cervical cancer cell lines (HeLa,
SiHa and C-33A) by immunocytochemistry and western blot
(Fig. 2). We found that RKIP is expressed at high levels in all cell
lines, and is present at both cytoplasm and nucleus of the cells
(Fig. 2A), as already described before [37]. All the cell lines were
used to knockdown the expression of RKIP by stable transfection
with PQY15 vector containing a short hairpin-RNA for RKIP
(shRKIP). The empty vector was also transfected as control. The
RKIP protein levels in these stable transfected cells were
determined by western blot analysis. As shown in Fig. 2B, RKIP
protein levels was efficiently inhibited in the shRKIP transfected
cells when compared to the empty vector transfected cells.
To explore the role of RKIP in the modulation of EGF
stimulated ERK signaling in cervical cancer, the transfected cells
were stimulated with EGF, and EGFR and ERK phosphorylation
levels were assessed by western blot. As it can be observed in
Fig. 2B, EGF stimulation did not result in significant effects in the
activation of ERK signaling in these cells, independently of RKIP
status.
Role of RKIP Expression in Cervical Cancer Cell Lines
Biological Behavior
To assess whether the modulation of RKIP expression
influenced the tumorigenic properties of the cells, we chose the
cell line with highest level of RKIP inhibition by shRKIP, HeLa
and measured in vitro its viability, proliferation, anchorage
independent growth and migration capabilities (Fig. 3). We
observed that shRKIP transfected cells have a significant viability
advantage over time (Fig. 3A), when compared with the empty
vector transfected cells (p,0.05). This difference may be a
reflection of an increased cell number or it may reflect increased
cellular metabolism. To see whether this viability advantage was
due to higher proliferation rates, we studied the effect of RKIP on
BrdU incorporation, cell cycle distribution and anchorage-
independent growth. The BrdU assay, confirmed that shRKIP
transfected cells have a significant proliferative advantage over
time (Fig. 3B). The soft agar colony formation assay demonstrated
a significant (p,0.05) increase in the number of the colonies
formed in the shRKIP transfected cells when compared to the
control cells (Fig. 3C). By cell cycle analysis, we observed that
shRKIP transfected cells had a decreased G0/G1 phase with a
concomitant and significant (p,0.05) increase in the G2/M+S
phase (Fig. 3D). These results were further validated in the other
two transfected cell lines, SiHa and C-33A (Fig. S1A–D).
Finally, to address the effect of RKIP in HeLa cells migration,
we performed wound healing migration assay and observed that
shRKIP transfected cells had a migration advantage over time,
with a significant (p,0.05) higher rate of wound closure when
compared with the control cells (Fig. 3E). The same was observed
in the other two transfected cell lines, SiHa and C-33A (Fig. S1E–
F).
In vivo Role of RKIP Expression in Cervical Cancer Growth
and Angiogenesis
To examine the effect of RKIP-mediated tumor growth and
angiogenesis in vivo, we performed the CAM assay (Fig. 4). The
transfected cells were implanted into the CAM of the chick
embryo (empty vector cells, n = 10; shRKIP cells, n = 10), and
seven days after cell implantation, the chicken embryos were
sacrificed to evaluate tumor growth and angiogenesis, as described
in materials and methods section. The mean perimeter of the
tumors formed by the control and the shRKIP transfected cells
was 43356823 mm and 491361568 mm, respectively. As shown in
Fig. 4B, the size of the tumors formed by shRKIP cells was not
significantly higher when compared to the tumors formed by the
empty vector cells.
To evaluate the impact of RKIP in angiogenesis modulation, we
counted ex ovo the number of vessels around the tumors. We
counted a mean of 54616 and 83610 vessels in the tumors
formed by the empty vector and the shRKIP transfected cells,
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respectively. RKIP inhibited cells revealed a statistically significant
(p,0.05) increase in blood vessels recruitment when compared to
the control cells (Fig. 4D). As shown in Fig. 4C, the hematoxylin-
eosin staining of the paraffin embedded tumors and CAM’s
confirmed the rich vascularization of the tumors with capillaries
around the tumor and capillaries sprouting out of the CAM into
the tumors. Higher rates of vascularization were observed in the
tumors formed by shRKIP transfected cells (Fig. 4C).
Role of RKIP in Cervical Cancer Cells Response to
Chemotherapy
To determine whether RKIP protein could be involved in the
modulation of cervical cancer patient’s response to the conven-
tional chemotherapy, we determined the sensibility of cervical
cancer cell lines transfected with shRKIP to cisplatin treatment. As
it can be observed in the cytotoxic assays (Fig. 5A), all the shRKIP
transfected cell lines were less sensitive to cisplatin treatment, when
compared to the control cell lines transfected with the empty
vector, being this difference less evident for C-33A cell line. As
shown in Fig. 5B, HeLa cells transfected with the shRKIP
displayed a mean IC50 of 18.5562.06 mM against the
5.9160.30 mM reached by the empty vector cells. For C-33A cell
line the values were more similar between the two transfected cell
lines, 10.3762.69 mM and 13.2561.98 mM for the empty vector
and the shRKIP transfected cells, respectively (Fig. 5B). The SiHa
Figure 1. Immunohistochemistry analysis of RKIP in cervical tissues. A) Positive expression in a cervicitis. B) High-grade squamous
intraepithelial lesion with negative expression. C) Adenocarcinoma tissue depicting positive expression. D) Negative adenocarcinoma (*) with
adjacent normal cells (arrow) depicting positive staining. All the pictures were taken with at 2006magnification.
doi:10.1371/journal.pone.0059104.g001
Table 2. Correlations between RKIP expression and cervical
cancer patient’s clinical data.
RKIP Expression
Parameter N
Negative
(%)
Positive
(%) p
Age (years)
.49 15 12 (80) 3 (20) 0.805
#49 18 15 (83.3) 3 (16.7)
Metastasis*
Absent 48 42 (87.5) 6 (12.5) 0.728
Lymph node 5 4 (80.0) 1 (20.0)
Distant 14 13 (92.9) 1 (7.1)
Follow-up (months ± SD) 72 123.666.8 95.4610.9 0.938*
*Log-rank test determined by Kaplan-Meier method.
doi:10.1371/journal.pone.0059104.t002
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cell line was the less sensitive to cisplatin with the empty vector
transfected cells reaching 25.9960.51 mM of mean IC50, while the
shRKIP transfected cells reached 40.6962.37 mM of mean IC50
for cisplatin (Fig. 5B).
To explore the mechanisms by which RKIP induces resistance
to cisplatin in cervical cancer cell lines, we exposed HeLa cells to
increasing concentrations of cisplatin during 24 hours (Fig. 5C),
and found that cisplatin treatment induced ERK activation in
both cell lines, more evident for higher doses, but shRKIP
transfected cells were more resistant to cisplatin induced PARP
and capase-9 cleavage (Fig. 5C). Thus, RKIP seems to modulate
cervical cancer cells response to cisplatin chemotherapy by
controlling apoptosis.
Discussion
The role played by HPV in cervical cancer initiation is well
known; however, the molecular pathways involved in the
progression and metastasization processes remains unclear [6].
While the broad use of Papanicolaou smear screening has led to a
decline in mortality from cervical cancer, many patients still died
of the disease, mainly due to cancer metastasis [44]. Therefore, it is
important to elucidate the mechanisms involved in cervical cancer
aggressiveness and metastisation.
In cancer, RKIP is considered to be a metastasis suppressor
gene, being downregulated during the metastatic process of
distinct tumors [18,20–23]. In the present study, we studied the
protein expression levels of RKIP not only in cervical cancer, but
also in non-malignant lesions (cervicitis and intraepithelial lesions).
In general, we found that RKIP is highly expressed at the
cytoplasm in the benign lesions (54% of the samples; 73/135), but
is significantly (p,0.05) reduced in cervical cancer (independently
of the histological subtype), with only ,15% (19/124) of the
samples staining positively. No associations were found between
RKIP expression and the presence of metastasis. Also, no
correlations were found between the remaining patient’s clinico-
pathological data or survival, which limits its use as prognostic
marker. However, further studies, involving a larger number of
Figure 2. Effect of RKIP on ERK pathway activation in HeLa cells. A) Immunocytochemistry analysis for RKIP in HeLa, SiHa and C-33A cells
showing both nuclear and cytoplasmatic expression. B) For RKIP inhibition, the cell lines were stably transfected with a shRNA for RKIP and with the
respective empty vector for control. RKIP expression levels were assessed by western blot. Further, the cells were stimulated with 10 ng/ml of EGF by
10 minutes and EGFR and ERK activation (phosphorylation) was assessed by western blot for phospho-ERK1/2 and phospho-EGFR expression, but no
significant differences were observed. E: Empty vector; Sh: ShRKIP.
doi:10.1371/journal.pone.0059104.g002
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Figure 3. In vitro role of RKIP in HeLa cells biological behavior. A) Cellular viability and B) Proliferation was measured at 24, 48 and 72 hours
by MTS and BrdU assays, respectively. RKIP inhibited cells had a statistically significant viability and proliferative advantage over time, when
compared to control cells. C) Cells were assayed for their ability to proliferate in growth medium containing 0.35% agar and the formation of multi-
cellular colonies photographed at x16 magnification after 14 days. RKIP inhibition induces a statistically significant anchorage-independent growth of
HeLa cells in soft agar. D) Downregulation of RKIP in HeLa cells induced a shift on cell cycle distribution with a statistically significant higher
percentage of cells in G2M+S phase when compared to control cells. Cell cycle analysis was done at 24 hours’ time point by flow cytometric analysis
of propridium iodide stained cells. E) A standardized scratch (wound) was applied to monolayers and digital images were taken at several time points
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patients with a more comprehensive clinicopathological data
available, are needed to validate and extend our findings.
Additionally, it would be interesting to analyze the interplay
between RKIP and HPV infection. Hu CJ and colleagues have
recently reported results very similar to ours: the high expression of
RKIP in non-tumoral or pre-malignant lesions, and its significant
(0; 12; 24 and 48 hours). It was observed that shRKIP transfected cells had a statistically significant migration advantage over time, when compared to
control cells (right panel). Representative images at 0 and 48 hours are presented in the left panel. All the experiments were done in triplicate at least
three times. Data is represented as the mean 6 SD and differences with a p,0.05 on the two-way ANOVA or student’s t test were considered
statistically significant (*).
doi:10.1371/journal.pone.0059104.g003
Figure 4. In vivo role of RKIP in HeLa cells growth and angiogenesis. A) Representative pictures (166magnification) of CAM assay after 7
days of tumor growth in ovo and ex ovo. B) Tumor growth was measured in vivo by CAM assay as described in materials and methods section. It was
observed a higher perimeter (mM) of the tumors (in ovo) formed by shRKIP cells, however the difference between the control cells was not significant.
C) Hematoxylin-eosin staining of the paraffin embedded tumors showing the higher vascularization induced by RKIP inhibition. Representative
pictures with 106 and 206magnification are represented in the left panel. D) Counting of the blood vessels ex ovo, it was observed a statistically
significant increase on the number of vessels recruited in the tumors formed by shRKIP cells when compared to the control. In total it was analyzed
20 eggs (10 were injected with empty vector and 10 with shRKIP cells). The data is represented as the mean 6 SD and differences with a p,0.05 on
the Student’s t test were considered statistically significant (*).
doi:10.1371/journal.pone.0059104.g004
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lost in primary tumors of the cervix and in its lymph node
metastases. Similar to us, the authors did not found significant
correlation between RKIP positivity and clinical outcome [36]. In
many other studies, loss of RKIP protein has been associated with
poor prognosis [18,22,25–28,30,33,34], but at variance, many
studies, including ours, have come out showing the absence of
RKIP in primary tumors independently of associations with
presence of tumor metastasis or prognosis
[10,11,24,28,31,32,45,46].
RKIP action was first described as an inhibitor of the RAF-1-
MEK interaction, thereby preventing the activation of RAF/
MEK/ERK signal transduction [8]. Recently, several studies have
showed that RKIP is involved in more intracellular signaling
pathways. Stimulation of cells with a growth factor, such as EGF,
induces RKIP phosphorylation at S153 by protein kinase C
reduces the affinity of RKIP for c-RAF and enhances RKIP
binding to G-protein–coupled receptor kinase-2 [7,47]. Moreover,
RKIP suppresses the activation of the nuclear factor Kappa B
(NFkB) cell survival pathway by blocking the inactivation of the
inhibitor of NFkB, namely IkB [48]. More recently, it was shown
that RKIP binds GSK3 proteins and maintains GSK3b protein
levels and its active form [49]. The involvement of RKIP in signal
transduction pathways that are important regulators of growth,
motility, invasion and differentiation in cancer cells, re-enforce the
usefulness of functional studies to assess its role in tumors where its
expression is downregulated.
To understand the biological role of the reduction of RKIP in
cervical cancer specimens, we performed in vitro and in vivo studies
with three distinct cervical cancer cell lines. RKIP downregulation
was done by cells transfection with a specific shRNA for RKIP,
which resulted in the reduction of the protein levels, as already
described [37,50].
Firstly, we studied the role of RKIP in the control of cervical
cancer cells growth. We observed that cells with low levels of
RKIP had in vitro a viability advantage over time when compared
with cells with normal levels of RKIP. This viability advantage was
shown to be due to the high levels of proliferation of the cells, as
evidenced by BrdU and colony formation assays, which is
probably promoted by a shift in cell cycle distribution with a
higher percentage of cells in G2/M and S phase. The in vitro effect
of RKIP in cellular proliferation and cell cycle regulation has not
been consistent in the literature, and this may reflect in part the
assays used. Our data agrees with those of Li et al who obtained
similar results in ovarian cancer cell lines with regard to viability
and anchorage-independent growth [45]. Also, Lee et al found that
the proliferation of human hepatoma cells was reduced in cells
Figure 5. Role of RKIP in cervical cancer cells response to cisplatin. A) Representative pictures of the nonlinear regression analysis of cervical
cancer cell lines treated with cisplatin for determination of half maximal inhibitory concentrations (IC50). B) Graphic representation of the mean IC50
values for cisplatin in the cervical cancer cell lines. The transfected cells with shRKIP were less sensitive to cisplatin treatment in the three different cell
lines. C) HeLa transfected cell lines were exposed to increasing concentrations of cisplatin by 24 hours. Cisplatin treatment induced ERK activation (p-
ERK1/2) and apoptosis of the cells as evaluated by PARP (total and cleaded specific antibodies) and caspase-9 cleavage, mainly in the empty vector
transfected cells. All the experiments were done in triplicate at least three times. Data in the panels A and B are represented as the mean 6 SD.
doi:10.1371/journal.pone.0059104.g005
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overexpressing RKIP [51]. However, Schuierer et al reported that
RKIP did not influence melanoma cell proliferation in vitro [52],
an observation that was also supported using prostate cells [20].
Regarding cell cycle, our results were similar to those obtained by
other authors in ovarian and nasopharyngeal carcinomas [45,53].
However, previous studies with HeLa cells showed a change in
mitotic index but no significant change in cell proliferation [37].
In vivo, we did not observed differences in the size of the tumors
formed by RKIP inhibited cells when compared to control cells,
consistent with results from mouse xenograft models [19]. Dangi-
Garimella et al demonstrated that RKIP regulates invasion,
intravasation and metastasis in human breast cancer but does
not significantly alter primary tumor growth in vivo, consistent with
a role as a metastasis suppressor [19]. Thus, the discrepant in vitro
and in vivo findings suggest that RKIP function can be influenced
by the tumor microenvironment.
To explore the putative role of RKIP in the regulation of
cervical cancer metastasis, we studied the migratory and angio-
genic properties of RKIP downregulated cells. We found in vitro
that the absence of RKIP is related with higher migratory
capability of the cells, and in vivo that tumors formed by injection
of shRKIP cells were significantly more vascularized. Similar
results using wound healing migration assay were already obtained
with other cell types, such as kidney, fibroblasts and hepatoma
cells [12,50,51]. Concerning angiogenesis, our results are in
agreement with the results reported by Li et al, who reported the
low expression of RKIP associated with angiogenesis in a breast
cancer mouse model [54]. Likewise, Fu et al reported that
overexpression of RKIP reduces the angiogenic capacity and
vascular invasion in a prostate mouse model [20], this being a
crucial mechanism through which RKIP regulates metastasis.
Importantly, we observed a clear apoptotic resistance of cervical
cancer cells to cisplatin treatment associated with low levels of
RKIP expression. Other studies have shown that RKIP is also
involved in the regulation of tumor cells response to both radio
and chemotherapy. In drug-sensitive cell lines, down-regulation of
RKIP led to the resistance to DNA-damaging drugs (9-
nitrocamptothecin, taxol and cisplatin) [55]. Loss of RKIP
expression in cancers leads to transcriptional activation of NFkB
[48], resulting in a dramatic inhibition of apoptosis and the
development of chemoresistance [56–58]. In nasopharyngeal
carcinoma patients low expression of RKIP was associated with
radiotherapy resistance [53]. Recently, Al-Mulla F et al analyzed
the mechanisms through which RKIP induced chemotherapeutic
resistance [59]. Using colon cancer cell lines as models, they
reported a link between RKIP-KEAP 1-NRF2 to explain the drug
resistance induced by RKIP and suggest this pathway as a possible
target for personalized therapeutic intervention in RKIP depleted
cancers [59].
Based on these findings, therapies that can induce increased
RKIP expression can constitute interesting approaches. Locostatin
has been shown to abrogate the ability of RKIP to inhibit Raf-1.
Increasing the levels of RKIP expression re-sensitize cells to drug
induced apoptosis [60]. Rituximab has also shown to up-regulate
RKIP, which has been shown to sensitize non-Hodgkin’s
lymphoma cell lines to chemotherapeutic induced apoptosis
[61]. Furthermore, nitric oxide mediated chemo/immunosensiti-
zation via inhibition of NFkB may also involve the induction of
RKIP. Induction of RKIP inhibits anti-apoptotic pathways that
regulate tumor cell sensitivity to apoptotic stimuli [62].
Conclusions
In conclusion, we confirm that RKIP protein is significantly lost
in cervical carcinomas when compared with precursor lesions.
Furthermore, we found that RKIP downregulation in cervical
cancer cells is able to alter cell cycle distribution, induce higher
cellular survival, proliferation, migration and anchorage indepen-
dent growth in vitro. In contrast, no effects were observed in the
tumors growth in vivo, but it was found that RKIP inhibition is
associated with higher angiogenic rates in cervical cancer.
Furthermore, we observed that RKIP expression has an impact
on cervical cells effective response to cisplatin treatment.
Altogether, our results would indicate RKIP as a potential
biomarker for cervical cancer patients.
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Figure S1 In vitro role of RKIP in SiHa and C-33A cells
biological behavior. A–B) Cellular viability was measured by
MTS. RKIP inhibited cells had a statistically significant viability
advantage over time, when compared to control cells. C–D) Cells
were assayed for their ability to proliferate in growth medium
containing 0.35% agar and the formation of multi-cellular colonies
photographed at x16 magnification after 14 days. RKIP inhibition
induces a statistically significant anchorage-independent growth in
soft agar. E–F) A standardized scratch (wound) was applied to
monolayers and digital images were taken at several time points. It
was observed that shRKIP transfected cells had a statistically
significant migration advantage over time, when compared to
control cells. All the experiments were done in triplicate at least
three times. Data is represented as the mean 6 SD and differences
with a p,0.05 on the two-way ANOVA or student’s t test were
considered statistically significant (*).
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